Elevance Health Inc. (ELV) Stock
NYSEELV has an Alpha Score of 47 out of 100 (weak), computed on Nov 2, 2026 from 3 of 4 sub-scores. 14 members of Congress disclosed 33 trades in ELV since 2022: 19 purchases and 14 sales, most recently Alan Armstrong (purchase, Mar 27, 2026). 6 of the hedge funds AlphaScala tracks reported ELV in 13F filings for the quarter ended Jun 30, 2026; the largest reported position is Baupost Group's at $493.14M. Company insiders reported 0 open-market buys and 13 sales on SEC Form 4 in the 90 days to Oct 30, 2026. Its trailing P/E ratio is 18.9 and its net margin 2.5% (key statistics as of Oct 22, 2026).
What is ELV's Alpha Score?
How it works →Alpha Score of 47 reflects weak overall profile with strong momentum, weak value, weak quality. Based on 3 of 4 signals – score is capped at 90 until remaining data ingests.
Computed from 3 of 4 sub-scores; a sub-score is left out when its inputs are missing, and the composite is capped accordingly.
Computed Nov 2, 2026
A rules-based research rating, not a recommendation to buy or sell.
Which members of Congress traded Elevance Health Inc. (ELV)?
Most recent: Alan Armstrong (purchase, Mar 27, 2026); records start Dec 20, 2022.
| Politician | Trade date | Type | Amount |
|---|---|---|---|
| Alan Armstrong R-OK · Senate | 2026-03-27 | purchase | $1k – $15k |
| Markwayne Mullin R-OK · Senate | 2025-12-29 | purchase | $15k – $50k |
| Lisa McClain R-MI · House | 2025-08-13 | sale | $1k – $15k |
| Gil Cisneros D-CA · House | 2025-08-05 | purchase | $1k – $15k |
| Lisa McClain R-MI · House | 2025-07-10 | purchase | $1k – $15k |
| Lisa McClain R-MI · House | 2025-06-24 | purchase | $1k – $15k |
| Gil Cisneros D-CA · House | 2025-05-30 | sale | $1k – $15k |
| Rob Bresnahan R-PA · House | 2025-05-15 | sale | $15k – $50k |
From STOCK Act periodic transaction reports. House filings as of Oct 29, 2026. Senate records here end Oct 21, 2026; later Senate trades are not included.
Every member of Congress who traded ELV, with filing lags →Which hedge funds own ELV?
From 13F filings| Fund | Shares Held | Position Value | Change vs prior Q |
|---|---|---|---|
| Baupost Group Seth Klarman | 1.28M | $493.14M | n/a |
| Citadel Ken Griffin | 906K | $350.53M | -42% |
| Millennium Management Israel Englander | 728K | $281.37M | -21% |
| Renaissance Technologies Jim Simons (founder) | 201K | $77.88M | +1193% |
| D.E. Shaw David Shaw | 140K | $54.27M | -65% |
| Marshall Wace | 21K | $8.13M | +453% |
13F holdings as of Jun 30, 2026
Explore all tracked funds →Are Elevance Health Inc. insiders buying or selling?
SEC Form 4 filings| Date | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| Oct 22, 26 | Kaye Mark | EVP & CFO | SELL | 400 | $174K |
| Oct 22, 26 | Kaye Mark | EVP & CFO | SELL | 321 | $140K |
| Oct 22, 26 | Kaye Mark | EVP & CFO | SELL | 1.7K | $724K |
| Oct 22, 26 | Kaye Mark | EVP & CFO | SELL | 560 | $245K |
| Oct 22, 26 | Kaye Mark | EVP & CFO | SELL | 240 | $105K |
| Oct 22, 26 | Kaye Mark | EVP & CFO | SELL | 1.2K | $510K |
| Oct 22, 26 | Kaye Mark | EVP & CFO | SELL | 1.7K | $758K |
| Oct 22, 26 | Kaye Mark | EVP & CFO | SELL | 2.3K | $1.0M |
| Oct 22, 26 | Kaye Mark | EVP & CFO | SELL | 480 | $212K |
| Oct 22, 26 | Kaye Mark | EVP & CFO | SELL | 440 | $195K |
SEC Form 4 filings as of Oct 30, 2026
See cluster-buy signals across all tickers →What are ELV's key statistics?
Key statistics as of Oct 22, 2026
How does ELV's valuation compare with the Healthcare sector?
| Metric | ELV | Healthcare median | Companies in median |
|---|---|---|---|
| P/E ratio | 18.9 | 27.1 | 97 |
| Net margin | 2.47% | 5.48% | 139 |
| Return on equity | 11.24% | 6.84% | 158 |
| Dividend yield (payers) | 1.24% | 1.62% | 50 |
Medians over the Healthcare stocks whose key statistics were refreshed in the last 35 days (newest Nov 2, 2026). P/E excludes loss-making companies.
AlphaScala analysis on ELV
Latest 1ELV price chart
Powered by TradingViewWhat does Elevance Health Inc. do?
Elevance Health, Inc. is a leading health company that operates through key segments including Health Benefits, CarelonRx, Carelon Services, and Corporate and Other. The Health Benefits segment provides a comprehensive suite of commercial, Medicare, and Medicaid health plans, along with managed care options like preferred provider organizations, serving employers, individuals, families, and communities across multiple states via affiliates such as Anthem Blue Cross and Blue Shield and Wellpoint. CarelonRx delivers pharmacy services to both affiliated health plan members and external customers. Carelon Services integrates physical, behavioral, pharmacy, and social care to support whole health affordably through risk-based solutions, clinical expertise, and partnerships with health plans, government agencies, and providers. This holistic approach addresses physical, behavioral, and social needs, enhanced by digital tools and data insights for better outcomes, affordability, equity, and access. Founded in 1944 and headquartered in Indianapolis, Indiana, Elevance Health plays a pivotal role in the U.S. healthcare market by simplifying care delivery and advancing integrated health solutions for diverse populations.